Clinical trialRSSApr 30
Developer gets OK to expand first-in-human trial of ALS therapy to Europe
A company called Vectory Therapeutics has received permission to test its experimental ALS drug, called VTx-002, at hospitals in the United Kingdom and European Union. The drug is already being tested in the United States as part of a Phase 1/2 clinical trial. This expansion means more patients in Europe may have the opportunity to participate in this early-stage study of a potential new ALS treatment.
WHY IT MATTERSALS patients in the U.K. and EU now have access to a first-in-human trial for a novel therapy, potentially expanding treatment options beyond currently available medications for this rapidly progressive disease.